Business Wire

ROBOSENSE-LIDAR

29.7.2021 14:02:14 CEST | Business Wire | Press release

Share
RoboSense Partners with GAC Aion to Deliver Mass-produced Advanced Autonomous Vehicles with LiDAR

RoboSense LiDAR , the leading Smart LiDAR Sensor provider and GAC Aion New Energy Automobile Co., Ltd. (“GAC Aion”) set up by Guangzhou Automobile Group Co., Ltd (GAC Group,6601238.SH,02238.HK) , a Fortune 500 company and one of the automobile groups with the most complete industry chain in China jointly announced that GAC has selected RoboSense's second-generation intelligent solid-state LiDAR equipped with the ADiGO autonomous driving system,and will be mass-produced on a variety of autonomous driving models including the Aion LX of GAC Aion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005558/en/

ADiGO is an intelligent driving ecosystem led by GAC. This independently developed and interconnected ecosystem integrates smart factory, autopilot system, and IoT system. Powered by big data and various AI technologies, the self-driving system is available for mass production in L3 and is able to support L4 pilot running in some closed scenarios. The current ADiGO system on the Aion LX and Aion V uses a triple perception system (camera, millimeter wave radar, high-precision map) to achieve L3 autonomous driving in highway and urban expressway scenes.

The characteristics of Robosense's second-generation LiDAR active high-precision three-dimensional perception allows the ADiGO system to obtain more reliable perception information and ensure driving safety. It adopts a revolutionary two-dimensional MEMS smart chip scanning architecture and has a unique intelligent "GAZE" function, which can adjust the scanning method according to the driving scene, improve the perception of LiDAR, and help improve the performance and experience of autonomous driving. While achieving hardware intelligence verification, RS-LiDAR-Algorithm, the core of software intelligence, has more than 13-years of technology research and development accumulation. During the 5-year commercialization of LiDAR products, it has been verified by more than 100 partners in multiple scenarios around the world. Internally integrated AI perception algorithm, synchronously output 3D point cloud data and target-level environment perception results. The second-generation intelligent solid-state LiDAR helps the ADiGO system achieve a leap from safety to comfort in the driving experience under various road conditions.

In high-speed scenes, intelligent “GAZE” dynamically increases the vertical resolution of the ROI area, allowing the ADiGO system to find distant obstacles earlier, and enhance the autonomous driving experience on highways and urban expressways. In urban scenes, intelligent “GAZE” dynamically improves refresh the frame rate helps the ADiGO system respond more quickly to the dynamic changes of surrounding vehicles,pedestrians and other obstacles.

Due to technological innovation, the second-generation intelligent LiDAR can effectively control hardware costs, allowing more consumers to obtain a safer and more comfortable experience of autonomous driving. In the future, RoboSense will continue to promote technological innovation. Through the sustainable upgrad of intelligent LiDAR product system solution, it will work with partners to promote the intelligent car ecosystem.

About RoboSense (www.robosense.ai ):

RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.

About GAC Motor (https://www.gac-motor.com ):

Guangzhou Automobile Group Co., Ltd. (“GAC”) was incorporated in June 1997. In 2020, GAC’s production and sales both exceeded 2 million, with a positive year-on-year growth. Based on export planning, GAC Group successfully pushed ahead its international business, and GAC MOTOR was born with the right time.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye